Secondary metastasis resection after biomarker-stratified first-line treatment of metastatic colorectal carcinomaInterim analysis of the IVOPAK II study with a risk-benefit assessment of secondary metastatic resection.

Erbitux (cetuximab) - Eli Lilly

5-fluorouracil - Generic mfg.

irinotecan - Generic mfg.

Avastin (bevacizumab) - Roche

leucovorin calcium - Generic mfg.

Secondary metastasis resection after biomarker-stratified first-line treatment of metastatic colorectal carcinomaInterim analysis of the IVOPAK II study with a risk-benefit assessment of secondary metastatic resection. (PubMed, Oncology) - Oct 23, 2026 - "Following palliative biomarker-stratified first-line treatment for nonresectable metastatic colorectal carcinoma, the multimodal approach with secondary metastatic resection demonstrated a significant survival benefit."
Benefit-risk assessment • Biomarker • Journal • Colorectal Cancer • Oncology • Palliative care • Solid Tumor • BRAF • HER-2 • KRAS • PIK3CA

http://www.ncbi.nlm.nih.gov/pubmed/42905650

Arndt Hartmann; Axel Schmid; Axel Wein; Christian Krautz; Dagmar Busse; Juergen Siebler; Kerstin Wolff; Markus Eckstein; Markus Neurath; Maximilian Gerner; Peter Anhut; Robert Gruetzmann; Stephan Kersting; Susanne Merkel

Oct 23, 2026